Table 1. Baseline patient characteristics (n = 197).
| Variables | |
|---|---|
| Median age, years (range) | 57 (27–80) |
| ASA score, n (%) | |
| 1 | 51 (26.3) |
| 2 | 92 (47.4) |
| 3 | 50 (25.8) |
| 4 | 1 (0.5) |
| Not available | 3 (1.5) |
| Median BMI at diagnosis, kg/m2 (range) | 22.83 (16.38–35.84) |
| Median CA 125 level at diagnosis, U/mL (range) | 1825.7 (44.3–30000) |
| FIGO stage, n (%) | |
| IIIB | 7 (3.6) |
| IIIC | 45 (22.8) |
| IVA | 89 (45.2) |
| IVB | 56 (28.4) |
| Histologic type, n (%) | |
| Serous | 180 (91.4) |
| Mucinous | 4 (2.0) |
| Endometrioid | 3 (1.5) |
| Clear cell | 7 (3.6) |
| Others | 3 (1.5) |
| Radical surgery, n (%) | |
| None | 113 (57.36) |
| Bowel surgery | 30 (15.23) |
| VATS | 29 (14.72) |
| Splenectomy | 25 (12.69) |
| Liver resection | 17 (8.63) |
| SCF resection | 4 (2.03) |
| Breast/axillar LN dissection | 6 (3.05) |
| Ureter resection | 4 (2.03) |
| Others | 14 (7.11) |
| Methods of biopsy, n (%) | |
| Diagnostic laparoscopy | 119 (60.4) |
| Ascites | 56 (28.4) |
| Pleural effusion | 22 (11.2) |
| Residual disease after IDS, n (%) | |
| NGR | 72 (36.6) |
| ≤0.5 cm | 63 (32.0) |
| ≤1 cm | 27 (13.7) |
| ≤2 | 5 (2.5) |
| >2 | 8 (4.1) |
| Unknown | 22 (11.2) |
| Cycles of NAC, median (range) | 3 (1–9) |
| Number of NAC cycles, n (%) | |
| <4 | 152 (77.2) |
| ≥4 | 45 (22.8) |
| Cycles of POAC, median (range) | 5 (0–9) |
| Number of POAC cycles, n (%) | |
| <4 | 83 (42.1) |
| ≥4 | 114 (57.9) |
| Cycles of total chemotherapy (NAC+POAC), median (range) | 8 (3–12) |
| Number of total chemotherapy (NAC+POAC), n (%) | |
| <6 | 8 (4.1) |
| ≥6 | 189 (95.9) |
ASA, American Society of Anesthesiologists; BMI, body mass index; CA 125, cancer antigen 125; FIGO, Federation of Gynecology and Obstetrics; VATS, video-assisted thoracoscopic surgery; SCF, supraclavicular fossa; LN, lymph node; NGR, no gross residual disease; NAC, neoadjuvant chemotherapy; POAC, postoperative adjuvant chemotherapy